Updated strategies in Small Cell Lung Cancer post ASCO 2007

Small Cell Lung Cancer (SCLC) is associated with intensive nicotine consumption and characterized by a very aggressive growth rate. Furthermore, metastases often appear very early. At the annual meeting of the "American Society of Clinical Oncology" (ASCO) 2007, recent issues which will in...

Full description

Saved in:
Bibliographic Details
Published in:Wiener medizinische Wochenschrift 2007, Vol.157 (21-22), p.562
Main Authors: Hoschek, Stefan, Hoschek-Risslegger, Ursula, Fiegl, Michael, Zabernigg, August, Pall, Georg, Auberger, Thomas, Gunsilius, Eberhard, Schmid, Thomas, Jamnig, Herbert, Hilbe, Wolfgang
Format: Article
Language:ger
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - toxicity
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - radiotherapy
Clinical Trials, Phase III as Topic
Cranial Irradiation
Drug Delivery Systems
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lung Neoplasms - radiotherapy
Neoplasm Staging
Palliative Care
Polymorphism, Genetic - genetics
Prognosis
Radiotherapy, Adjuvant
Retreatment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small Cell Lung Cancer (SCLC) is associated with intensive nicotine consumption and characterized by a very aggressive growth rate. Furthermore, metastases often appear very early. At the annual meeting of the "American Society of Clinical Oncology" (ASCO) 2007, recent issues which will influence the daily clinical practice were presented. New chemotherapy combinations such as carboplatin/irinotecan or pemetrexed as well as targeted therapies e.g. bevacizumab in combination with chemotherapy could extend our therapeutic options. A genetic polymorphism, which influences the pharmacokinetic of irinotecan, turned out to be one reason for the different outcome of an irinotecan/cisplatin therapy in a Japanese and Northern American population. In the field of radiotherapy, a phase III study showed for the first time a significant benefit in overall survival by prophylactic cranial radiation in the setting of extensive disease.
ISSN:0043-5341
DOI:10.1007/s10354-007-0484-9